Relay Therapeutics, Inc. (RLAY) annual income statement — 8-year revenue, gross profit & net income history
| Sales/Revenue | 10.68M | 15.36M | 10.01M | 25.55M | 1.38M | 3.03M | 82.65M | 0 | 0 |
| Revenue Growth % | 39.04% | 53.44% | -60.83% | 1749.82% | -54.41% | -96.34% | - | - | - |
| Cost of Goods Sold | 599K | 3.56M | 0 | 0 | 0 | 0 | 3.55M | 2.85M | 2.15M |
| COGS % of Revenue | - | 23.17% | - | - | - | - | 4.29% | - | - |
| Gross Profit | 7.08M | 11.8M | 10.01M | 25.55M | 1.38M | 3.03M | 79.11M | -2.85M | -2.15M |
| Gross Margin % | 66.29% | 76.83% | 100% | 100% | 100% | 100% | 95.71% | - | - |
| Gross Profit Growth % | - | 17.9% | -60.83% | 1749.82% | -54.41% | -96.17% | 2880.49% | -32.08% | - |
| Operating Expenses | 306.54M | 314.54M | 382.48M | 398.55M | 300.66M | 367.73M | 134.9M | 84.05M | 49.89M |
| OpEx % of Revenue | - | 2048.43% | 3822.07% | 1560.11% | 21770.89% | 12140.21% | 163.21% | - | - |
| Selling, General & Admin | 49.75M | 56.71M | 76.59M | 74.95M | 65.98M | 57.39M | 38.59M | 13.74M | 8.86M |
| SG&A % of Revenue | - | 369.33% | 765.38% | 293.39% | 4777.55% | 1894.55% | 46.69% | - | - |
| Research & Development | 258.14M | 261.38M | 319.09M | 330.02M | 246.35M | 172.65M | 99.86M | 70.31M | 41.03M |
| R&D % of Revenue | - | 1702.27% | 3188.66% | 1291.86% | 17838.88% | 5699.9% | 120.82% | - | - |
| Other Operating Expenses | -1000K | -3.56M | -13.21M | -6.42M | -11.68M | 137.69M | -3.55M | 0 | -9K |
| Operating Income | -296.46M | -302.74M | -372.47M | -373M | -299.27M | -364.7M | -55.8M | -84.05M | -49.89M |
| Operating Margin % | -2776.61% | -1971.59% | -3722.07% | -1460.11% | -21670.89% | -12040.21% | -67.51% | - | - |
| Operating Income Growth % | - | 18.72% | 0.14% | -24.63% | 17.94% | -553.63% | 33.61% | -68.47% | - |
| EBITDA | -297.67M | -299.18M | -367M | -367.73M | -295.14M | -360.77M | -52.25M | -81.2M | -47.73M |
| EBITDA Margin % | -2787.93% | -1948.43% | -3667.47% | -1439.49% | -21371.83% | -11910.63% | -63.21% | - | - |
| EBITDA Growth % | 17.7% | 18.48% | 0.2% | -24.59% | 18.19% | -590.51% | 35.66% | -70.11% | - |
| D&A (Non-Cash Add-back) | -1.21M | 3.56M | 5.46M | 5.27M | 4.13M | 3.92M | 3.55M | 2.85M | 2.15M |
| EBIT | -212.13M | -276.48M | -385.67M | -379.42M | -310.95M | -227.01M | -55.8M | -84.05M | -48.78M |
| Net Interest Income | 19.22M | 27.04M | 34.75M | 31.05M | 8.79M | 830K | 3.4M | 8.8M | 0 |
| Interest Income | 24.57M | 27.04M | 34.75M | 31.05M | 8.79M | 830K | 3.4M | 8.8M | 1.11M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 23.75M | 26.26M | 34.76M | 31.03M | 8.77M | 826K | 3.38M | 8.74M | 1.1M |
| Pretax Income | -272.7M | -276.48M | -337.71M | -341.97M | -290.51M | -363.87M | -52.41M | -75.31M | -48.78M |
| Pretax Margin % | -2554.14% | -1800.58% | -3374.72% | -1338.66% | -21036.13% | -12012.94% | -63.41% | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -272.7M | -276.48M | -337.71M | -341.97M | -290.51M | -363.87M | -52.41M | -66.5M | -48.78M |
| Net Margin % | -2554.14% | -1800.58% | -3374.72% | -1338.66% | -21036.13% | -12012.94% | -63.41% | - | - |
| Net Income Growth % | 18.2% | 18.13% | 1.25% | -17.72% | 20.16% | -594.25% | 21.19% | -36.32% | - |
| Net Income (Continuing) | -272.7M | -276.48M | -337.71M | -341.97M | -290.51M | -363.87M | -52.41M | -75.31M | -48.78M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.52 | -1.61 | -2.36 | -2.79 | -2.59 | -3.82 | -2.56 | -15.53 | -19.63 |
| EPS Growth % | 29.6% | 31.78% | 15.41% | -7.72% | 32.2% | -49.22% | 83.52% | 20.89% | - |
| EPS (Basic) | - | -1.61 | -2.36 | -2.79 | -2.59 | -3.82 | -2.56 | -15.53 | -19.63 |
| Diluted Shares Outstanding | 179.85M | 171.59M | 142.87M | 122.58M | 112.23M | 95.14M | 90.19M | 4.28M | 2.49M |
| Basic Shares Outstanding | 179.85M | 171.59M | 142.87M | 122.58M | 112.23M | 95.14M | 90.05M | 4.28M | 2.49M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying RLAY stock.
For fiscal year 2025, Relay Therapeutics, Inc. (RLAY) reported total revenue of $15.4M.
Relay Therapeutics, Inc. (RLAY) reported a net loss of $276.5M for the fiscal year ending 2025.
Relay Therapeutics, Inc. (RLAY) reported an operating income of $-302.7M, resulting in an operating profit margin of -1971.6%. This margin reflects the operational efficiency of the business before interest and taxes.
Relay Therapeutics, Inc. (RLAY) generated $11.8M in gross profit for the year, representing a gross profit margin of 76.8%. This demonstrates the company's core pricing power and production efficiency.